Clicky

Synairgen Plc(SNG)

Description: Synairgen plc is a holding company. The Company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). The Company uses its human biology BioBank platform to discover and develop therapies for respiratory disease. Using the BioBank platform, it has developed a number of tissue models, which include In vitro and Ex vivo models. The Company's primary asset is AZD9412, which is an inhaled interferon beta (IFN-beta) therapy. AZD9412 is outlicensed to AstraZeneca for the clinical development and commercialization, and is in a confirmatory Phase II trial. Its drug programs include IFN-b (SNG001) for Asthma and COPD, and Lysyl oxidase-like protein 2 (LOXL2) inhibitors for IPF. The Company's subsidiary includes Synairgen Research Limited, which is engaged in the drug discovery and development.


Keywords: Bank Medicine Biology Disease Clinic Drug Discovery Asthma Beta Respiratory Diseases Respiratory Therapy Chronic Obstructive Pulmonary Disease In Vitro Fibrosis Idiopathic Pulmonary Fibrosis Copd Interferon Pulmonology Respirator Therapies Chronic Lower Respiratory Diseases Severe Asthma

Home Page: www.synairgen.com

SNG Technical Analysis

Mailpoint 810
Southampton, SO16 6YD
United Kingdom
Phone: 44 23 8051 2800


Officers

Name Title
Mr. Richard Marsden CEO, MD & Exec. Director
Prof. Stephen T. Holgate CBE, M.D. Co-Founder, Non-Exec. Director & Member of Scientific Advisory Board
Mr. John Ward CFO & Exec. Director
Dr. Phillip David Monk Chairman of Scientific Advisory Board, Chief Scientific Officer & Exec. Director
Prof. Donna Davies Co-Founder & Member of Scientific Advisory Board
Prof. Ratko Djukanovic Co-Founder & Member of Scientific Advisory Board
Ms. Brooke S Clarke Sr. VP & Head of Communications
Dr. Gareth E. Walters Ph.D. Chief Regulatory Officer
Ms. Jody Brookes Sr. VP & Head of Clinical Operations
Mr. Richard Hennings Chief Commercial Officer

Exchange: LSE

Country: UK

Currency: Pence sterling (p)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.293
Price-to-Sales TTM: 759.0013
IPO Date:
Fiscal Year End: December
Full Time Employees: 24
Back to stocks